Last checked at 22 Jul 2021 07:00
REACH - Non-regulatory announcement
Nuformix plc
("Nuformix" or the "Company")
Letter to shareholders re: Dr Anne Brindley
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that further to the RNS issued yesterday on the departure of Dr Anne Brindley as CEO, the Company has issued a letter to shareholders. The letter can be viewed here: https://nuformix.com/document-center/
Enquiries:
Nuformix plc | via Walbrook | ||||
Dr Alastair Riddell, Non-Executive Chairman |
| ||||
Dr Anne Brindley, CEO |
| ||||
|
| ||||
Allenby Capital Limited | +44 (0) 20 3328 5656 | ||||
Nick Athanas / George Payne (Corporate Finance) |
| ||||
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) |
| ||||
|
| ||||
Walbrook PR | nuformix@walbrookpr.com or +44 (0)20 7933 8780 | ||||
Anna Dunphy / Paul McManus / Kiki Zaccagnini | Tel: +44 (0)7876 741 001 / +44 (0)7980 541 893 | ||||
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.